Physician profile
Sharon Yee
NPI 1336427814
$21,575.59
in general payments reported to CMS, 2019-2025
42 companies · $4,040 in 2025
The $4,040 reported for 2025 was more than what 81% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,073 · 2020: $2,211 · 2021: $3,042 · 2022: $1,906 · 2023: $4,537 · 2024: $3,767 · 2025: $4,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $283 · Consulting Fee: $66.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,994.08 |
| Education | $282.93 |
| Consulting Fee | $66.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,320.62 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,567.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,953.79 | 2019-2025 | |
| Genentech USA, INC. | $900.19 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $837.27 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Amgen INC. | $783.54 | 2021-2025 | Tezspire, Actimmune |
| Optinose US, INC. | $672.09 | 2019-2025 | |
| Pfizer INC. | $622.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $608.36 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $593.83 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $537.81 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Alk-Abello, INC | $535.19 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Csl Behring | $310.77 | 2019-2025 | Hizentra, Haegarda |
| Octapharma USA, INC. | $310.12 | 2019-2023 | Cutaquig |
| Blueprint Medicines Corporation | $290.31 | 2023-2024 | Ayvakit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.